Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced key presentations of clinical and scientific data at the 54th Annual Meeting of the American Society of Hematology (ASH), being held in Atlanta, Georgia, from December 8-11, 2012. The presentations include two oral presentations and 10 poster presentations for ZEVALIN® (ibritumomab tiuxetan) injection for intravenous use, three poster presentations for FOLOTYN® (pralatrexate injection), and four poster presentations for belinostat, a novel histone deacetylase (HDAC) inhibitor.
“Nearly 20 presentations at ASH will feature clinical and scientific data for Spectrum’s commercial products, ZEVALIN and FOLOTYN, as well as our late-stage drug candidate, belinostat,” said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. “The ZEVALIN-related abstracts demonstrate its use in a multitude of diverse settings and potential indications in which this product is being tested, including transplantation, its use in elderly patients, in frontline treatment and in the treatment of relapsed/refractory disease, as well as in new drug combinations. The FOLOTYN-related abstracts include presentations on new, synergistic combinations with other approved agents and in difficult-to-treat indications, such as HTLV-1-induced leukemia/lymphoma, while belinostat-related presentations are studying new combinations and indications, such as in refractory AML/MDS, as well as research on this promising drug candidate’s mechanism of action.”
For more information about the ASH annual meeting and for a complete list of abstracts, please refer to the conference Web site at https://ash.confex.com/ash/2012/webprogram/start.html.
The following are key ZEVALIN-related abstracts being presented at the ASH meeting:
|Abstract #||Type||Title||First Author||Date/Time Location|
|1978||Poster||Autologous Stem Cell Transplantation with Yttriumm-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial||Briones||Saturday, Dec. 8 5:30 PM-7:30 PM Hall B1-B2|
|2742||Poster||RIT with 90Y Ibritumomab Tiuxetan in Patients with Non-Hodgkin Lymphoma Over 65 Years||Andrade||Sunday, Dec. 9, 6:00 PM-8:00 PM Hall B1-B2|
|2687||Poster||A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402)||Witzig||Sunday, Dec. 9, 6:00 PM-8:00 PM Hall B1-B2|
|2726||Poster||90-Yttrium Ibritumomab Tiuxetan (Zevalin) and BEAM Chemotherapy (Z-BEAM) Vs BEAM for Autologous Stem Cell Transplantation in Lymphoma: Toxicity and Long Term Outcome From a Retrospective Multicentric Study of 123 Patients||Terriou||Sunday, Dec. 9, 6:00 PM-8:00 PM Hall B1-B2|
|2729||Poster||Rituximab-PECC Induction Followed by 90y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study||Lugtenburg||Sunday, Dec 9, 6:00 PM-8:00 PM Hall B1-B2|
|2753||Poster||Phase I Trial of Combination Therapy with 90y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin’s Lymphoma, Final Report||Borghaei||Sunday, Dec. 9, 6:00 PM-8:00 PM Hall B1-B2|
|3019||Poster||Collection of Hematopoietic Stem Cells After Previous Exposure to Ittrium-90 Ibritumumab Tiuxetan (Zevalin) Is Feasible and Does Not Impair Autologous Stem Cell Transplantation Outcome in Follicular Lymphoma||Derenzini||Sunday, Dec. 9, 6:00 PM-8:00 PM Hall B1-B2|
|747||Oral||Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin||Kolstad||Monday, Dec. 10, 5:00 PM B312-B313a|
|3657||Poster||Short Course of Bendamustine and Rituximab Followed by 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Early Results of "Fol-Brite"||Lansigan||Monday, Dec. 10, 6:00 PM-8:00 PM Hall B1-B2|
|3648||Poster||FDG-PET/CT Early After 90Y-Ibritumomab Tiuxetan Therapy Predicts Outcome in Relapsed or Refractory Indolent B-Cell Lymphoma||Okada||Monday, Dec. 10, 6:00 PM-8:00 PM Hall B1-B2|
|3681||Poster||Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Υ-Radioimmunotherapy and Maintenance Rituximab||Berinstein||Monday, Dec. 10, 6:00 PM-8:00 PM Hall B1-B2|
|812||Oral||Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma||Fruchart||Monday, Dec. 10 6:30 PM B312-B313a|
|Abstract #||Type||Title||First Author||Location|
|2735||Poster||Pralatrexate in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A New York City Multi-Institutional Experience||Lunning||Sunday, Dec. 9, 6:00 PM-8:00 PM Hall B1-B2|
|2758||Poster||Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate||Jain||Sunday, Dec. 9, 6:00 PM-8:00 PM Hall B1-B2|
|3660||Poster||Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma||Parker||Monday, Dec. 10, 6:00 PM-8:00 PM Hall B1-B2|
|Abstract #||Type||Title||First Author||Location|
|1359||Poster||Mechanisms of Sensitivity and Resistance to Histone Deacetylase Inhibitors in Diffuse Large B-Cell Lymphoma||Tula-Sanchez||Saturday, Dec. 8, 5:30 PM-7:30 PM Hall B1-B2|
|2725||Poster||Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease||Amengual||Sunday, Dec. 9, 6:00 PM-8:00 PM Hall B1-B2|
|3588||Poster||Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update||Holkova||Monday, Dec. 10, 6:00 PM-8:00 PM Hall B1-B2|
|3891||Poster||Inhibition of Histone Deacetylase Activity Compromises Homologous Recombination Repair and Increases Sensitivity of Chemo-Resistant Chronic Lymphocytic Leukemia Cells to Olaparib||Agathanggelou||Monday, Dec. 10, 6:00 PM-8:00 PM Hall B1-B2|
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV